Drug intelligence / Profile preview

PB203

Development stage: Preclinical
Lead developer: Panolos Bioscience
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

PB203 is a multi-specific protein drug developed by Panolos Bioscience. It is currently in preclinical development for the treatment of solid tumors, specifically pancreatic ductal adenocarcinoma and intrahepatic cholangiocarcinoma. Chime Biologics provides comprehensive Chemistry, Manufacturing, and Controls (CMC) services for PB203, utilizing its CHOrus platform for cell line development, process development, and GMP manufacturing to support its progression to clinical trials and global commercialization. Plans are in place for Phase I clinical trials in the US.

Targets

PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on PB203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB203.

Explore the full profile